FTC challenges drug patents: The Commission argues “junk” patent listings stifle competition and keep drug prices high. We explore what consumers stand to gain via the FTC’s challenge—and its likelihood of success.
Moderna prepping for RSV vaccine launch this fall: We explore how, if approved, the vaccine could open up a new market for the company—and the competitive edge its shot could hold in the entrenched RSV space.
Gen Zers and millennials are embracing healthier habits: They want to invest in both their short- and long-term health. Here’s how health and wellness brands and marketers can seize the opportunity.
Pfizer developing direct-to-consumer platform: We unpack the move and explore why Pfizer won’t be the last pharma player to provide patients with easier access to its medications.
CVS’ Medicare Advantage business is taking some hits: Aetna’s senior members are getting a lot of care, which is driving up costs. Their insurance benefits are likely going to be scaled back as a result.
Optum discontinues its in-house telehealth business: We explore three reasons that could have driven Optum’s decision.
Marketing payments to docs drove Rx volume: But pharma marketers will need to do more than just pay for physicians’ meals to build long-lasting relationships.
Walmart shuts down Walmart Health, Virtual Care businesses: We unpack how common pitfalls faced by other providers plagued Walmart Health—and what the future could hold for the retail health space.
Moderna, OpenAI make genAI pact: Pharma execs have taken a mostly cautious approach with AI. But new market pressures will drive more accelerated adoption of the tech.
US drug spending is on the rise: The 13.5% increase in 2023 was largely driven by weight loss meds. We explore the broader implications for US healthcare—and how and when this spending should be addressed.
Nurses protest AI in healthcare: Concerns center on a perceived rush to implement untested, unregulated tech. This piles on nurses’ laundry list of issues with their employers—the pressure is mounting on hospitals to respond.
What the FTC’s noncompete ban means for healthcare providers: 40% of physicians are bound by noncompetes. While it might take a while to enforce, it could shift power from employers back to doctors.
Walgreens expands specialty pharmacy services: It’s pulling back on primary care while getting deeper into specialty pharmacy. Can it catch up to CVS, Cigna, and United?
TikTok pulls out the stopwatch on GLP-1 content: It’s restricting most content related to weight loss drugs. We explore what this means for health influencers and the pharma marketers who sponsor them.
US falls short on primary care access: We explore how historical underinvestment in primary care has created a big market opportunity for nontraditional players.
Headspace launches D2C mental health services: The rollout bucks recent digital health market trends. We unpack some of the factors that could ultimately make Headspace’s D2C push a wise move.
A new wave of obesity drugs in the US: GLP-1s have been lauded as a potential game-changer for the US’ obesity epidemic. We explore how they also hold the potential to widen already persistent health disparities.
CVS, Oak Street to embed retail pharmacy with primary care: Will the co-located retail health model run into the same problems as Walgreens/VillageMD?
Elevance Health forms a primary care JV: We explore why all industry stakeholders must be paying attention to healthcare “payviders.”
US physicians’ views on genAI are shifting: While doctors’ positive stance on genAI presents a massive opportunity for vendors and patients alike, their outlook comes with a catch—the tech has to be vetted. AI developers, take note.